HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lauder overhauls e-commerce site

This article was originally published in The Rose Sheet

Executive Summary

Firm's newly redesigned e-commerce Web site "tak[es] the guesswork out if shopping online," providing consumer with "a seamless experience from the Web site to the counter," according to Oct. 21 announcement. In addition to new "intuitive" product layout, site features company's Skincare Finder interactive diagnostic tool, which matches consumer with skin-care regimen tailored to her individual needs based on her responses to a series of questions. Online shoppers can also access Lauder's Foundation Finder, which identifies an ideal shade based on input related to skin intensity, undertone and type, as well as individual coverage preference; application tips from the pros also are provided, firm notes. Site additionally contains step-by-step instructional videos for achieving different makeup effects, such as smoky eyes, sculpted cheeks and classic lips. Personal profiles for Lauder spokesmodels - and their "current beauty must-haves" - are available as well. With more customers doing their shopping online, "we want to ensure [the consumer] is able to get the information and support she needs to make the best choices," says Elana Drell Szyfer, Estee Lauder's senior VP-global marketing

You may also be interested in...



Formycon Chief Sees COVID-19 Boosting Biosimilars

Formycon’s CEO has offered the latest indication that the coronavirus outbreak could provide a tailwind for biosimilars, as the firm gave an update on its biosimilars pipeline – including ranibizumab, ustekinumab, aflibercept and an undisclosed molecule, as well as other unrevealed projects – and how it has been affected by the pandemic.

PDUFA Renewal Negotiations: What Does Industry Want Now?

With the formal, virtual kick-off meeting set for 23 July, US FDA and sponsors are looking at a transformed landscape as they discuss what the next five years of user fees will look like.

Keeping Track: Approvals For Phexxi, Kynombi; New Claims For Lynparza, Alunbrig, Tecentriq; Intercept May Miss NASH User Fee Date

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.

UsernamePublicRestriction

Register

WI964834

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel